Investigation of the influence of the multifiltrate dialysis method on the serum levels of ceftazidime and avibactam (Zavicefta) in intensive care patients requiring dialysis
- Conditions
- Infections caused by pathogens sensitive to ceftazidime/avibactamAcute or acute-on-chronic renal failure requiring continuous dialysis treatment
- Registration Number
- DRKS00029362
- Lead Sponsor
- Center of Breath ResearchKlinik für Anästhesiologie, Intensivmedizin und SchmerztherapieUniversitätsklinikum des Saarlandes
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 15
Written consent of the patient or his/her legal guardian, patient > 18 years of age, acute renal failure with indication for continuous renal replacement therapy, patient already receiving ceftazidime/avibactam or administration is planned for medical indication, central venous catheter for taking blood samples has already been placed for medical indication , BMI < 35, for women of childbearing potential: negative pregnancy test, or previous surgical sterilization or use of contraceptives during the examination or at least 2 years after postmenopause.
Refusal by the patient, contraindications or known intolerance to one of the medications or procedures used, previous illnesses or patient circumstances that make an examination of the patient impossible or impractical (e.g. dementia, psychiatric diseases, lack of understanding of speech or speech), body mass index > 35 , pregnancy.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration course of ceftazidime/avibactam with and without multifiltration dialysis<br>1. before first delivery<br>2. 15 min after initial administration<br>3. 30 min after initial administration<br>4. 60 min after initial administration<br>5. 90 min after initial administration<br>6. 120 min after initial administration<br>7. 180 min after initial administration<br>8. 240 min after initial administration<br>9. 300 min after initial administration<br>10. 360 min after initial administration
- Secondary Outcome Measures
Name Time Method change in distribution volumes and clearance values; Correlation between ceftazidime/avibactam dosage and plasma concentrations considering the cofactors: acute renal failure, multifiltration dialysis, ceftazidime/avibactam in the dialysis filtrate. The endpoints are calculated after all plasma measurements have been completed within a pharmacokinetic model.